biohaven

Transforming the Treatment of Disease to Improve Lives

Biohaven is a unique experienced team dedicated to creating a world where people live healthier lives by transforming the treatment of neurological and neuropsychiatric diseases, including rare disorders. Our commitment to patients drives us to follow the path of science and motivates us to overcome the obstacles in bringing innovative medicines to those in need.

In the pursuit of our mission, we operate with purpose and urgency to turn breakthrough discoveries into best-in-class therapies for diseases with little or no treatment options. We know that patients are waiting and days matter. It's why we operate as a modern pharmaceutical company that is agile and inventive, and ready to execute our patient-first commitment with innovative ideas and steadfast focus.

Fueled by our entrepreneurial structure and our proven drug development capabilities, Biohaven is poised to create a better future for the people who count on us.

WINNING WITH SCIENCE

As we race to set a new course in the treatment of disease, we are committed to relentlessly drive the science and optimizing innovation at every turn. Leveraging our proprietary platforms and discovery research capabilities, we are advancing a portfolio of paradigm-shifting treatment options and challenging the standard to improve the lives of people with debilitating diseases.



Investor Relations: **Jennifer Porcelli** | +1 201-248-0741

Media Contact: **Mike Beyer** | +1 312-961-2502

KV7 ION CHANNEL MODULATION PLATFORM:
EPILEPSY AND NEURONAL HYPEREXCITABILITY

The lead asset in our Kv7 platform is BHV-7000 (formerly known as KB-3061), which is specifically designed to target potassium channels without engagement of gamma aminobutyric acid (GABA) receptors. The lead indication being sought for BHV-7000 is focal epilepsy, which is the most common form of epilepsy and affects approximately 3.5 million Americans and more than 50 million people worldwide. BHV-7000 also has rare pediatric disease designation from the U.S. Food and Drug Administration.

GLUTAMATE PLATFORM:
IMPULSE CONTROL AND NEUROLOGICAL DISORDERS

Biohaven is developing the next generation of agents aimed at normalizing glutamate via two distinct mechanisms: glutamate-transporter modulation (troriluzole) or N-methylD-aspartate (NMDA) receptor antagonism. Our glutamate modulation platform is comprised of two product candidates: troriluzole (BHV-4157) and BHV-5000/5500. Troriluzole is currently being evaluated in late-stage clinical trials for spinocerebellar ataxia (SCA) and obsessive-compulsive disorder (OCD).

MYOSTATIN INHIBITION PLATFORM:
NEUROMUSCULAR DISEASES

In patients with neuromuscular diseases, myostatin, a natural negative regulator of muscle growth, can limit the growth needed to achieve normal developmental and functional milestones. The lead asset in our myostatin platform is taldefgrobep alfa, an investigational, muscle-targeted recombinant protein with the potential to enhance muscle mass and strength in people living with spinal muscular atrophy (SMA) used in combination with other approved treatments. We are currently enrolling patients in a Phase 3 clinical trial in SMA.

DISCOVERY RESEARCH:
CREATING PATIENT VALUE THROUGH NOVEL PLATFORMS

Biohaven is also developing novel drug candidates for the treatment of diseases with high unmet medical needs based on its proprietary, next-generation bispecific technology platforms and other innovative approaches:

ARM™ – Next Generation Bispecifics Molecules

Our antibody recruiting molecule (ARM) BHV-1100, in combination with autologous cytokine induced memory-like (CIML) natural killer (NK) cells and immune globulin (Ig), is expected to target and kill multiple myeloma cells expressing the cell surface protein CD38. Biohaven has initiated dosing in a Phase 1a/1b trial in newly diagnosed multiple myeloma patients.

TRPM3 Channel Antagonists

Our channel antagonist program is focused on advancing chemically distinct oral backup molecules for persistent pain states. TRPM3 is a novel druggable target in the transient receptor potential (TRP) channel family. Preclinical models and human genetic validation implicate TRPM3 in pain signaling. The lead clinical candidate in our TRPM3 discovery program is BHV-2100, a first-in-class TRPM3 antagonist for neuropathic pain.

AT A GLANCE

Employees

200+ globally

Locations

New Haven, CT (headquarters)
Cambridge, MA
Yardley, PA
Pittsburgh, PA
Dublin, Ireland

Executive Management

Vlad Coric, M.D.
Chairman and Chief Executive Officer

Matthew Buten
Chief Financial Officer

Clifford Bechtold
President and General Manager, Biohaven Ireland, Chief Compliance Officer

Irfan Qureshi, M.D.
Chief Medical Officer

Bruce Car, Ph.D.
Chief Scientific Officer

Michael Bozik, M.D.
President, Ion Channel Research & Development

Steven Dworetsky, Ph.D.
Senior Vice President, Ion Channel Research & Development

Tanya Fischer, M.D., Ph.D.
Chief Development Officer and Head of Translational Medicine

biohaven

Corporate

Biohaven, Ltd.
Kingston Chambers
PO Box 173
Road Town, Tortola
British Virgin Islands

United States

Biohaven Pharmaceuticals, Inc.
215 Church Street
New Haven, Connecticut 06510